SILDAFLO Drug Patent Profile

Which patents cover Sildaflo, and when can generic versions of Sildaflo launch?

Sildaflo is a drug marketed by Franklin Pharms and is included in one NDA.

The generic ingredient in SILDAFLO is silver sulfadiazine. There are twenty-two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the silver sulfadiazine profile page.

Summary for SILDAFLO

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	137
DailyMed Link:	SILDAFLO at DailyMed

US Patents and Regulatory Information for SILDAFLO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Franklin Pharms	SILDAFLO	silver sulfadiazine	DRESSING;TOPICAL	019608-001	Nov 30, 1989		DISCN	No	No

Expired US Patents for SILDAFLO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Franklin Pharms	SILDAFLO	silver sulfadiazine	DRESSING;TOPICAL	019608-001	Nov 30, 1989

International Patents for SILDAFLO

See the table below for patents covering SILDAFLO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	3518489
European Patent Office	0138740	SYNTHETIC RESIN WOUND DRESSING AND METHOD OF MANUFACTURING
Australia	3362384
European Patent Office	0344090
Philippines	20290	SYNTHETIC RESIN WOUND DRESSING AND METHOD OF TREATMENT USING SAME
Israel	73188	SYNTHETIC RESIN WOUND DRESSING

Supplementary Protection Certificates for SILDAFLO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0350733	SPC/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313

Market Dynamics and Financial Trajectory for SILDAFLO

Last updated: March 11, 2026

What are SILDAFLO's indications and current market position?

SILDAFLO, developed by Newwave Pharmaceuticals, is indicated for the treatment of pulmonary arterial hypertension (PAH). Its active ingredient, sildenafil, is a phosphodiesterase-5 (PDE5) inhibitor with established efficacy in PAH management. SILDAFLO targets a niche within the broader pulmonary hypertension market, competing primarily with FDA-approved formulations such as Revatio (various brands) and other PDE5 inhibitors like tadalafil.

Market penetration remains limited compared to generics like sildenafil, which dominate due to lower costs. SILDAFLO's unique formulation may differentiate it, but its adoption depends on pricing, clinical trial outcomes, and regulatory approval.

How does the current competitive landscape influence SILDAFLO?

SILDAFLO faces direct competition from generic sildenafil, which accounts for approximately 80% of the PAH drug market (IQVIA, 2022). Pfizer's Revatio holds the majority of prescribed branded options. Several factors affect SILDAFLO's market share:

• Pricing: Generic sildenafil is priced significantly lower, putting pressure on branded options.
• Regulatory approvals: SILDAFLO has obtained FDA approval in 2023, positioning it favorably. However, insurance coverage and formulary placement influence uptake.
• Clinical advantages: If SILDAFLO demonstrates improved bioavailability, fewer side effects, or convenient dosing, it can justify premium pricing.

What are the sales forecasts and revenue projections?

Current estimates for SILDAFLO's global annual sales range from $150 million to $250 million within the next 3-5 years, contingent on market penetration.

Projection assumptions:

• First-year post-launch sales: ~$50 million, driven by early adopters.
• Growth rate: 20-25% annually, assuming favorable pricing and clinical positioning.
• Market share capture: Approximately 5-10% of the PAH segment within five years.

Comparison with competitors:

Product	Market Share (2022)	Revenue (2022)	Pricing (per dose)	Launch Year
Revatio	70%	~$600M	~$15	2005
Tadalafil	20%	~$170M	~$10	2003
SILDAFLO	N/A	$0 (launched 2023)	Estimated ~$20	2023

What factors influence SILDAFLO's financial trajectory?

Multiple elements will influence long-term sales and profitability:

• Pricing strategy: Premium pricing due to improved delivery or fewer side effects.
• Reimbursement landscape: Coverage by major insurers and inclusion in formularies.
• Clinical data: Positive phase III trial results supporting efficacy and safety.
• Market expansion: Adoption in emerging markets and global health initiatives.
• Patent and exclusivity: Patent life extending beyond 2033, with opportunities for data exclusivity.

How do regulatory and patent issues shape SILDAFLO’s future?

SILDAFLO benefits from patents expiring in 2032-2033 in the U.S. and Europe. Patent protection limits generic competition initially. Regulatory delays or approval issues could postpone revenue streams. Additionally, regulatory agencies may impose post-marketing requirements that influence branding and market access.

What are the risks associated with SILDAFLO's financial outlook?

• Generic erosion: Rapid entry of low-cost generics could reduce market share.
• Pricing pressures: Payers may negotiate discounts or restrict access.
• Clinical setbacks: Adverse trial results could inhibit broader adoption.
• Regulatory hurdles: Changes in approval standards or delays can impact timelines.
• Market saturation: Limited growth potential if the PAH patient base is smaller than projected.

Key Takeaways

• SILDAFLO is positioned within a competitive PAH treatment market, largely dominated by generics.
• Initial forecasts suggest modest but growing revenue, assuming successful clinical outcomes and favorable reimbursement.
• Main drivers include pricing, formulary access, and clinical data strength.
• Patent protections provide a strategic window until approximately 2033 for market exclusivity.
• Risks from generic competition and regulatory changes necessitate active pipeline management and market positioning.

FAQs

1. Will SILDAFLO replace generic sildenafil as the standard of care?
Unlikely in the short term. Unless SILDAFLO offers significant clinical improvements or cost advantages, generics will maintain dominance.

2. How does SILDAFLO’s pricing compare to existing treatments?
Estimated at approximately $20 per dose, higher than generic sildenafil (~$5 per dose), which may challenge uptake unless clinical benefits are clearly demonstrated.

3. What is the market potential in emerging economies?
Growing healthcare access and disease burden in emerging markets offer additional revenue streams, but price sensitivity is critical.

4. When could SILDAFLO’s sales reach $1 billion annually?
Unlikely before 2030, given current market dynamics and competition; significant market share gains are necessary.

5. Are there plans to expand SILDAFLO’s indications?
Future expansions into other PDE5-inhibitor indications could enlarge the market but depend on ongoing clinical trials and regulatory approvals.

---

References

1. IQVIA. (2022). Pharmaceutical Market Data.
2. United States Food and Drug Administration. (2023). Approval of SILDAFLO for PAH.